Research

STX2171, a 17 beta-hydroxysteroid dehydrogenase type 3 (17 beta-HSD3) inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model


Reference:

Day, J. M., Foster, P. A., Tutill, H. J., Schmidlin, F., Hargrave, J. D., Vicker, N., Potter, B. V. L., Reed, M. J. and Purohit, A., 2012. STX2171, a 17 beta-hydroxysteroid dehydrogenase type 3 (17 beta-HSD3) inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model. Endocrine-Related Cancer, 20 (1), pp. 53-64.

Related documents:

This repository does not currently have the full-text of this item.
You may be able to access a copy if URLs are provided below. (Contact Author)

Official URL:

http://dx.doi.org/10.1530/ERC-12-0231

Details

Item Type Articles
CreatorsDay, J. M., Foster, P. A., Tutill, H. J., Schmidlin, F., Hargrave, J. D., Vicker, N., Potter, B. V. L., Reed, M. J. and Purohit, A.
DOI10.1530/ERC-12-0231
DepartmentsFaculty of Science > Pharmacy & Pharmacology
RefereedNo
StatusPublished
ID Code23238
Additional InformationMeeting abstract from 92nd Meeting and Expo of the Endocrine Society (ENDO 2010). 19-22 June 2010. San Diego, CA. Suppl. 1

Export

Actions (login required)

View Item